The question behind “asymptomatic bacteriuria pregnancy” is whether bacteria in your urine need treatment when you feel well. In pregnancy, clinicians usually screen with a urine culture and treat significant growth because bacteria can progress to a kidney infection. The approach differs from care for most healthy adults who are not pregnant, in whom screening and antibiotics for bacteria without symptoms are generally discouraged.
Asymptomatic Bacteriuria Pregnancy Screening: What Counts?
Asymptomatic bacteriuria means bacteria are present in urine at a significant level without urinary symptoms. A urine culture identifies the bacteria and estimates their quantity; a urine dipstick alone does not establish the diagnosis. Many guidelines use at least 100,000 colony-forming units per millilitre (CFU/mL) in a midstream sample as the threshold for significant growth.
There is a technical distinction between the definition and everyday screening. The Infectious Diseases Society of America describes asymptomatic bacteriuria in women using two consecutive urine samples with the same bacteria at this level. In prenatal care, however, screening often relies on one early-pregnancy culture. If a result says “mixed flora” or suggests contamination, your clinician may ask for another carefully collected sample rather than assume it is a confirmed infection.
Group B Streptococcus (GBS) in urine needs particular attention: it can have implications for pregnancy and newborn care beyond the usual decision about treating a urine infection. Ask your maternity team how the organism and count in your result affect your care; local protocols matter.
Why Pregnancy Changes The Decision
Pregnancy changes the urinary tract in ways that can make it easier for bacteria to ascend toward the kidneys. A kidney infection, or pyelonephritis, can cause serious illness. The U.S. Preventive Services Task Force (USPSTF) recommends screening pregnant people with a urine culture and concluded that screening and treatment have a moderate net benefit. It recommends against routine screening in nonpregnant adults, where antibiotics bring harms without a demonstrated overall benefit.
Treatment evidence supports caution as well as action. A 2019 systematic review by Aireen Wingert and colleagues, prepared to inform the Canadian Task Force on Preventive Health Care, examined studies of screening and antibiotic treatment in pregnancy. The treatment trials suggested fewer cases of pyelonephritis and low birth weight with antibiotics, but the evidence was low quality, and the size of the benefit—and how well results apply to routine prenatal care—remains uncertain. This helps explain why pregnancy is treated differently, but does not mean every trace of bacteria needs antibiotics.
Guidelines Differ On Timing And Repeat Testing
Major guidance agrees that a significant positive culture in pregnancy generally warrants treatment, but recommendations about screening frequency and follow-up are not identical. The USPSTF’s 2019 recommendation supports screening during pregnancy. Canadian guidance recommends one culture in the first trimester, though its recommendation was weak and based on very-low-quality evidence. UK NICE guidance calls for a midstream culture early in pregnancy and an immediate antibiotic prescription for asymptomatic bacteriuria. A 2020 joint report from four Brazilian medical societies recommends screening early and again at the start of the third trimester.
After treatment, whether to repeat a culture is less settled. Older U.S. obstetric guidance summarized in a 2019 guideline review recommended a test of cure, while the IDSA said evidence was insufficient to determine whether repeat screening is needed after treatment. The Brazilian report recommends a post-treatment culture in pregnancy. These differences reflect limited evidence, not proof that one follow-up schedule is best for everyone. Ask whether your care team wants a test of cure and when it should be collected.
For a confirmed infection, the antibiotic should be selected using the culture’s susceptibility results and pregnancy-specific safety considerations. IDSA guidance recommends 4–7 days of treatment, but rates the evidence for duration as weak and low quality. Your clinician can explain the choice for your result. For more on how treatment choices are made, read our guide to antibiotics for urinary tract infections in pregnancy.
When To Contact Your Care Team
If you have burning or pain when urinating, new urinary symptoms, fever, or pain in your side or back, contact your clinician promptly rather than treating the result as an asymptomatic finding. Symptoms may change the assessment and urgency. If you feel well but your culture is positive, ask what organism grew, the CFU/mL count, whether the sample may have been contaminated, and whether a follow-up culture is planned. This article cannot determine what a specific result means for you; your maternity clinician can interpret it in context.